

Annex I

List of the names, pharmaceutical forms, strength of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States

Member State in EEA	Marketing authorisation holder	Invented name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Cyprus	MEDA Pharmaceuticals S.A. 3, Evritanias Str. GR-15231 Chalandri-Attiki Greece	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Finland	MEDA Oy Vaisalantie 4 FIN-02130 Espoo Finland	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Finland	MEDA Oy Vaisalantie 4 FIN-02130 Espoo Finland	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	10 mg/5 ml
France	MEDA Pharma S.A.S. 25, Boulevard de l'Amiral Bruix F-75016 Paris France	Novantrone 10 mg/5 ml, solution à diluer pour perfusion	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
France	MEDA Pharma S.A.S. 25, Boulevard de l'Amiral Bruix F-75016 Paris France	Novantrone 20 mg/10 ml, solution à diluer pour perfusion	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml

Member State in EEA	Marketing authorisation holder	Invented name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
France	MEDA Pharma S.A.S. 25, Boulevard de l'Amiral Bruix F-75016 Paris France	Elsep 2 mg/ml, solution à diluer pour perfusion	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Germany	MEDA Pharma GmbH & Co. KG Benzstrasse 1 61352 Bad Homburg Germany	Novantron 10 mg/5 ml	2 mg/ml	Concentrate for solution for infusion or solution for intrapleural or intraperitoneal use	Intravenous use Intrapleural use Intraperitoneal use	10 mg/5 ml
Germany	MEDA Pharma GmbH & Co. KG Benzstrasse 1 61352 Bad Homburg Germany	Novantron 20 mg/10 ml	2 mg/ml	Concentrate for solution for infusion or solution for intrapleural or intraperitoneal use	Intravenous use Intrapleural use Intraperitoneal use	20 mg/10 ml
Germany	MEDA Pharma GmbH & Co. KG Benzstrasse 1 61352 Bad Homburg Germany	Ralenova 2 mg/ml	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Germany	MEDA Pharma GmbH & Co. KG Benzstrasse 1 61352 Bad Homburg Germany	Ralenova 2 mg/ml	2 mg/ml	Concentrate for solution for infusion	Intravenous use	10 mg/5 ml

Member State in EEA	Marketing authorisation holder	Invented name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Greece	MEDA Pharmaceuticals S.A. 3, Evritanias Str. GR-15231 Chalandri-Attiki Greece	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Iceland	MEDA AB Pipers vag 2A, Box 906 SE-170 09 Solna Sweden	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Iceland	MEDA AB Pipers vag 2A, Box 906 SE-170 09 Solna Sweden	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	10 mg/5 ml
Italy	MEDA Pharma S.p.A. Viale Brenta 18 IT-20139 Milano Italy	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	10 mg/5 ml
Italy	MEDA Pharma S.p.A. Viale Brenta 18 IT-20139 Milano Italy	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml

Member State in EEA	Marketing authorisation holder	Invented name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Norway	MEDA A/S Askerveien 61 NO-1384 Asker Norway	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	10 mg/5 ml
Romania	MEDA Pharma GmbH & Co. KG Benzstrasse 1 61352 Bad Homburg Germany	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Slovenia	MEDA Pharma GmbH & Co. KG Benzstrasse 1 61352 Bad Homburg Germany	Novantrone	2 mg/ml	Concentrate for solution for injection / infusion	Intravenous use	20 mg/10 ml
Spain	MEDA Pharma S.A.U. Edificio Berlin - Parque Empresarial San Fernando, Avda Castilla 2, 2 ^a planta E-28830 SAN FERNANDO DE HENARES (MADRID) Spain	Novantrone 20 mg solución inyectable	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml
Sweden	MEDA AB Pipers vag 2A, Box 906 SE-170 09 Solna Sweden	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	20 mg/10 ml

Member State in EEA	Marketing authorisation holder	Invented name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Sweden	MEDA AB Pipers vag 2A, Box 906 SE-170 09 Solna Sweden	Novantrone	2 mg/ml	Concentrate for solution for infusion	Intravenous use	10 mg/5 ml